Symbio Pharmaceuticals Limited

Symbio Pharmaceuticals Limited

0.47
USD
+0.19
(+65.95%)
-0.55EPS
Feb 11Next Earn

Important Dates

Symbio Pharmaceuticals Ltd's next confirmed earnings release is scheduled for February 11, 2027.

Earnings Date2/11/2027

Share Statistics

As of September 30, 2026, Symbio Pharmaceuticals Ltd has 80.21M shares outstanding.

Shares Outstanding80.21M

Financial Position

As of September 30, 2026, Symbio Pharmaceuticals Ltd maintains a current ratio of 0.40, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -61.74, indicating conservative leverage, while an interest coverage ratio of -123.32 demonstrates limited ability to service its debt obligations.

Current Ratio0.40
Quick Ratio0.11
Debt / Equity-61.74
Debt / EBITDA-0.13
Interest Coverage-123.32

Financial Efficiency

USD

These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -220.97, reflecting losses generated across the asset base. The company generates approximately 73,954.19 in revenue per employee across its workforce of 91.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.31 indicates how many times Symbio Pharmaceuticals Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-220.97
Revenue Per Employee73,954.19
Employee Count91.00
Inventory Turnover1.31

Taxes

USD

Over the twelve months ended September 30, 2026, Symbio Pharmaceuticals Ltd recorded 272,221.16 in income tax expense. The company reported a pretax loss of -38.43M and -38.71M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax272,221.16

Stock Price Statistics

As of the close on November 5, 2026, Symbio Pharmaceuticals Ltd's stock has declined approximately 45.41% over the past 52 weeks.

52-Week Price Change-45.41%

Income Statement

USD

Over the twelve months ended September 30, 2026, Symbio Pharmaceuticals Ltd generated 6.73M in revenue and converted that into -38.71M in net income, yielding earnings per share of -0.55. EBITDA reached -37.95M, while operating income came in at -37.95M.

Revenue6.73M
Gross Profit4.95M
Operating Income-37.95M
Pretax Income-38.43M
Net Income-38.71M
EBITDA-37.95M
EBIT-37.95M
Earnings Per Share (EPS)-0.55

Balance Sheet

USD

As of September 30, 2026, Symbio Pharmaceuticals Ltd holds 1.61M in cash and equivalents against 5.08M in total debt, resulting in a net debt position of 3.47M. Total book value stands at -8.23M, with working capital of -8.46M providing operational flexibility.

Cash & Cash Equivalents1.61M
Total Debt5.08M
Net Debt3.47M
Equity (Book Value)-8.23M
Book Value Per Share-0.10
Working Capital-8.46M

Margins

Over the twelve months ended September 30, 2026, Symbio Pharmaceuticals Ltd posted a gross margin of 73.48, reflecting its pricing power and cost economics. The operating margin of -563.97 and net profit margin of -575.15 provide insight into operational efficiency.

Gross Margin73.48
Operating Margin-563.97
Pretax Margin-571.11
Profit Margin-575.15
EBITDA Margin-563.97

Stock Splits

Symbio Pharmaceuticals Ltd's most recent stock split took place on October 29, 2019 with a 4:1 split ratio.

Last Split Date10/29/2019
Split Ratio4:1